Australian drug maker InterPharma will not appeal a ruling that dismissed its challenge to the validity of global pharmaceutical giant Pfizer’s patent for sedative drug Precedex.
The Australian Securities and Investments Commission has won its bid to use evidence from US proceedings in its case against Rio Tinto alleging the mining giant misled shareholders about a Mozambique mining company purchased for US$4.2 billion.
An appeals court has upheld a ruling that found two firms previously run by Joseph “Diamond Joe” Gutnik and his family were insolvent, ending a long-running battle over hundreds of millions of dollars in mining assets.
A court has thrown out a breach of contract claim brought by two subsidiaries of property developer Minster Group against National Australia Bank, but found the bank must face a $1.2 million unconscionability claim over allegedly excessive fees.
National Australia Bank is setting aside a further $1.18 billion to compensate customers for dodgy adviser service fees, consumer credit insurance sales, and non-compliant advice.
The NSW government’s Sydney Olympic Park Authority, which is facing a class action brought by owners of apartments at the troubled Opal Tower, has laid the blame on the developer, designer and builder behind the project.
The law firm behind multiple government class actions over major construction projects, including the Sydney Light Rail proceeding, is investigating a new case against a Melbourne council after a major development allegedly left local businesses struggling to survive.
At caretaker at a Sydney private school has been awarded $3.1 million in damages after he was seriously injured in a workplace gas explosion, with five defendants including building contractors, certifiers and gas suppliers all found to be equally liable.
Global solar panel manufacturer Hanwha Q CELLS wants to amend the patent behind its solar technology, more than six months after launching infringement proceedings against three rivals.
The University of Sydney has emerged triumphant in its long running battle over the intellectual property rights of a glaucoma testing device, with the Federal Court ruling against opthalmic diagnostic tool manufacturer ObjectiVision.